I et internationalt, enkelt arm, open- label fase 3b klinisk forsøg (ENHANCE) modtog i alt 2378 voksne patienter med svær sepsis drotrecogin alfa (aktiveret).
A total of 2378 adult patients with severe sepsis received drotrecogin alfa (activated) in a Phase 3b, international, single-arm, open-label clinical trial (ENHANCE).